Open Biosystems' Open Access RNAi Program Provides CIC bioGUNE with shRNAmir Technology; Open Biosystems Gains Momentum in European RNAi Market

Business Wire, May 11, 2006

HUNTSVILLE, Ala. -- Open Biosystems, Inc., focused on the commercialization of leading-edge life science research tools for drug discovery, today announced that Bilbao, Spain-based CIC bioGUNE has joined its Open Access RNAi Program. Through this program, CIC bioGUNE has purchased Open Biosystems' whole-genome human retroviral shRNAmir library.

With a commitment to accelerating research processes that lead to innovation, CIC bioGUNE is focused on optimizing its technological and scientific capacities to identify, prevent and cure disease. Consistent with the organization's stated goals, RNAi is a valuable research tool that is experiencing rapid adoption and leading to unprecedented developments in the treatment and diagnosis of disease. Open Biosystems' Open Access Program provides CIC bioGUNE's affiliated researchers with access to a whole-genome retroviral library without imposing heavy financial burdens. The program also provides CIC bioGUNE with the ability to freely distribute the library within the institution, and a dedicated technical support team including scientific site visits. The program also offers an off-site backup for the library.

"Open Biosystems' shRNAmir technology is the most advanced RNAi tool available. As we strive to lead Spain's bioscience research efforts, it is crucial that we utilize the most advanced research tools available. However, like most institutions, we are confined by costs," said Jose Maria Mato, institute director, CIC bioGUNE. "Open Biosystems' Open Access Program is the ideal solution. Our researchers now have access to the most advanced RNAi technology without the costs typically associated with such tools."

Open Biosystems' whole-genome retroviral shRNAmir library design is based on the understanding of natural RNAi pathways creating more specific and effective RNAi. As a result, CIC bioGUNE researchers can target any gene in the human genome with improved gene knockdown efficiency.

"RNAi is an innovative research tool that is gaining popularity around the world as scientists and researchers realize and witness its value," said Brian Pollock, chief executive officer and co-founder of Open Biosystems. "By providing broad availability of RNAi resources across whole institutions, the Open Access Program creates a collaboration that encourages and supports scientific advancements. CIC bioGUNE is one of many institutions that can benefit from this approach."

Additional information about Open Biosystems' Open Access RNAi Program can be found online at: www.openbiosystems.com/OpenAccessRNAi.> About RNAi

RNAi is a mechanism cells use to naturally regulate gene expression. It is being increasingly harnessed as a tool to identify and understand genes that function in the disease process, especially in cancer research. Open Biosystems is the leading provider of mammalian RNAi resources and its RNAi portfolio includes leading-edge technology incorporating advances in shRNA design and captured in whole genome microRNA-adapted shRNA (shRNAmir) libraries. Open Biosystems' shRNAmir libraries are proven to provide greater gene knockdown and fewer off-target effects than other RNAi systems.

About Open Biosystems

Open Biosystems, Inc. develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories. These research tools provide investigators with standardized high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders. Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama. For more information and details for ordering, please visit www.openbiosystems.com.